Data on the long-term management of patient receiving adalimumabfor hidradenitis suppurativa (HS) are scarce and mainly derived fromthe period 2 of the PIONEER studies. The aim of our retrospective study was to review epidemiologicaldata and analyze the therapeutic response, adverse effects, duration,and reasons of short suspension periods (SSP) during long-term anti-TNFαtherapy, in a real-life setting

Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience

Bettoli V.
Primo
;
Manfredini M.
Secondo
;
CALAMO, GIADA;Bencivelli D.;Corazza M.
Ultimo
2018

Abstract

Data on the long-term management of patient receiving adalimumabfor hidradenitis suppurativa (HS) are scarce and mainly derived fromthe period 2 of the PIONEER studies. The aim of our retrospective study was to review epidemiologicaldata and analyze the therapeutic response, adverse effects, duration,and reasons of short suspension periods (SSP) during long-term anti-TNFαtherapy, in a real-life setting
Bettoli, V.; Manfredini, M.; Calamo, Giada; Forconi, R.; Bencivelli, D.; Mantovani, L.; Pellacani, G.; Corazza, M.
File in questo prodotto:
File Dimensione Formato  
Bettoli_et_al-2018-Dermatologic_Therapy.pdf

solo gestori archivio

Descrizione: Full text editoriale
Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 1.07 MB
Formato Adobe PDF
1.07 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11392/2407204
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 18
social impact